Real-time polymerase chain reaction (PCR) of saliva is highly sensitive for newborn congenital cytomegalovirus (CMV) screening. This study uses nationally published CMV seroprevalence and breastfeeding rates to estimate the contribution of CMV DNA in breast milk to false-positive saliva PCR results. The false-positive rates adjusted for breastfeeding ranged from 0.03% in white Hispanic persons to 0.14% in white non-Hispanic persons. Saliva CMV PCR for newborn screening is highly sensitive, and the low false-positive rates in this study suggest that saliva PCR results are unlikely to be significantly influenced by breastfeeding or other perinatal exposures.
Congenital cytomegalovirus (CMV) infection (cCMV) is the most common congenital infection and a leading cause of sensorineural hearing loss (SNHL). The majority of infants with cCMV have no clinical symptoms at birth; however, 10%-15% of these infants will develop long-term sequelae. Thus, screening of all newborns for cCMV would allow for early identification and intervention to improve outcome.
Traditionally, testing for the presence of CMV in saliva and/ or urine of neonates using culture-based methods has been the standard for the diagnosis of cCMV because virus is shed in high quantities from these sites [1] . However, culture-based methods are labor intensive for widespread or universal newborn screening. Recently, we demonstrated in a large, prospective study of newborns that real-time polymerase chain reaction (PCR) of saliva is highly sensitive (>97%) and specific (99.9%) for newborn CMV screening [2] and will identify more infants with cCMV compared with traditional rapid culture techniques [3] . Additionally, PCR-based methods can be adapted to a high-throughput platform for large-scale newborn screening. Another advantage for saliva is the ease of collection of newborn saliva samples compared with urine specimens.
Although saliva PCR is currently the best option for cCMV screening, there are concerns that CMV present in breast milk could lead to false-positive results when using saliva PCR for newborn CMV screening. This study examined saliva false-positive screening rates from the CMV and Hearing Multicenter Screening (CHIMES) Study in the context of nationally published CMV seroprevalence and breastfeeding rates to estimate the possible contribution of CMV in breast milk to false-positive saliva PCR results when using saliva samples for newborn cCMV screening.
METHODS
From March 2007 to March 2012, infants born at 7 US hospitals were enrolled in the CHIMES study [2, 4] Newborn CMV screening was initially carried out by rapid culture of saliva specimens and PCR of dried blood spot as described previously [2] [3] [4] . Between June 2008 and December 2009, newborn saliva specimens were screened by rapid culture and PCR, and thereafter newborn samples were tested by PCR followed by rapid culture of PCR-positive specimens. The CMV screening data between June 2008 and March 2012 were analyzed for this study to determine the false-positive saliva PCR results. Infants with a positive saliva or dried blood spot screening test were enrolled in follow-up to confirm cCMV, and at the time of confirmation visit, saliva and urine samples were obtained and tested for CMV. Infants were considered to have confirmed cCMV if the follow-up urine or saliva sample was positive by rapid culture or PCR. Infants were considered to have false-positive screening results if they were positive on saliva PCR screening but negative on confirmatory testing of urine and/or saliva [2] . Local institutional review board approval was obtained at each site.
Because the CHIMES study did not collect data on maternal CMV seropositivity rates or breastfeeding information for the infants in the cohort, we used data previously reported in the literature for estimates of maternal CMV seroprevelance and breastfeeding rates. To estimate maternal CMV seropositivity rates, we used the National Health and Nutrition Examination Surveys (NHANES) nationally representative data on sex-and race-specific CMV seroprevelance rates during the period 1988-2004 [5] . To estimate expected breastfeeding rates, we used the National Immunization Survey (NIS) data from 2013 that were analyzed by the US Centers for Disease Control and Prevention (CDC) [6] . Using these data and the false-positive rate by race and ethnicity from the CHIMES study, the contribution of breastfeeding by CMV-seropositive mothers on newborn saliva CMV screening was estimated. In deriving these estimates, we assumed that all false positives in the cohort were attributable to infant breastfeeding. To obtain the estimated denominator of at-risk infants, we used the following formula: number of infants × percentage of CMV-seropositive mothers × percentage of breastfeeding mothers × estimated expected shedding of CMV in the colostrum. In deriving these estimates, 100% shedding of CMV in the colostrum was assumed. Due to the lack of national CMV seroprevalence data in Asian and multiracial women, 100% seroprevalence was assumed for calculation of adjusted false-positive rates in these populations. The exact 95% confidence intervals (CIs) for false-positive rates were calculated for each estimate.
RESULTS
Of the 74 788 infants screened at birth by saliva PCR for cCMV between June 2008 and March 2012, 307 (0.4%) infants tested positive. The mean age (± SD) of the newborns at the time of saliva sample collection for screening was 1.0 ± 1.0 days. The mean age (± SD) of the infants at the time of confirmation saliva and urine sample collection was 5 ± 5 weeks (5 infants with confirmation samples collected after 1 year of age were removed from this analysis). Of these infants 49.3% were female, 36.8%
were non-Hispanic white, 34.3% were Hispanic white, 23.1% were non-Hispanic black, 3.2% were Asian, and 2.6% were multiracial. Most of the screened infants resided in the well-baby nurseries (97.2%) and had public or no insurance (67.0%) for their hospital stay.
Of the 307 infants who screened positive for CMV by saliva PCR, 284 of the total 74 788 infants were confirmed to be CMV positive (0.38%; 95% CI, .34%-.43%) and 23 of the total 74 788 infants were negative on confirmatory testing (0.03%; 95% CI, 0.02%-0.05%). Among infants who screened positive, 7.5% (n = 23/307) were considered to be false positive based on the results of the confirmatory testing. The median viral load of the false-positive saliva screening samples was significantly lower (4.88 × 10 3 IU/mL; range, 5.81 × 10 2 -8.14 × 10 6 ) compared with screening saliva samples from infants confirmed to have cCMV (2.25 × 10 6 IU/mL; range, 1.16 × 10 2 -1.74 × 10 10 ; P < .001). The false-positive rate did not significantly vary based on race and ethnicity, with a rate of 0.03% (95% CI, .01%-.08%) in non-Hispanic black infants; 0.04% (95% CI, .02%-0.07%) in non-Hispanic white infants; 0.02% (95% CI, .01%-.05%) in Hispanic white infants; 0.04% (95% CI, .00%-.23%) in Asian infants; and 0.05% (95% CI, .00%-.29%) in multiracial infants.
The contribution of breastfeeding to the false-positive rate of saliva PCR was estimated by race and ethnicity based on the national CMV seroprevalence data and breastfeeding rates for these groups. The first row of Table 1 displays how the estimates were derived, with the source of data and/or computation shown for columns A-E. Assuming 100% shedding of CMV in the colostrum, we found the saliva false-positive rate in non-Hispanic black infants was 0.08% (95% CI, .03%-.17%) ( Table 1) . The false-positive rate was highest in non-Hispanic white infants b Data from CMV and Hearing Multicenter Screening (CHIMES) Study study [2] . c Cytomegalovirus seroprevalence rates in women aged 20-29 derived from the National Health and Nutrition Examination Surveys data [5] d Breastfeeding rates derived from National Immunization Survey [6] .
e Cytomegalovirus seroprevalence assumed to be 100%. at 0.14% (95% CI, .06%-.125%) and lowest in Hispanic white infants (0.03%; 95% CI, .01%-.07%). Adjusted estimates of the saliva CMV screening false-positive rates due to breastfeeding for Asian and multiracial infants were 0.05% (95% CI, .001%-.28%) and 0.07% (95% CI, .001%-.37%), respectively.
DISCUSSION
We estimate that the false-positive rates for saliva cCMV screening adjusted for CMV seroprevalence and breastfeeding are very low in the first week of life, ranging from 0.03% in Hispanic white infants to 0.14% in Non-Hispanic white infants. We have previously reported that saliva PCR for newborn cCMV screening is highly sensitive, with an overall unadjusted false-positive rate of <.03% [2] . The findings of this study show slight differences in the saliva PCR false-positive rates among the infants in the various ethnic and racial groups, likely due to the varying maternal CMV seroprevalence and breast feeding rates within these ethnic and racial groups in the United States. However, these factors did not significantly impact the saliva CMV PCR false-positive rate in the study infants.
Previous studies have established that CMV is shed in the breast milk of the majority of CMV-seropositive women with viral load levels peaking at approximately 1 month postpartum [7] [8] [9] . Therefore, there has been a concern that CMV in breast milk may contribute to false-positive saliva PCR testing, leading to expensive and unnecessary follow-up testing along with parental anxiety. However, the findings of our study indicate that breastfeeding in the first week of life contributes a low but acceptable false-positive rate for saliva PCR.
A limitation of our study is the impact of breastfeeding on saliva PCR for newborn CMV screening could not be directly examined because of the lack of maternal CMV seroprevalence and breastfeeding data in the study cohort. However, the usage of the nationally representative race-specific breastfeeding and seroprevalence rates allowed us to assess whether breastfeeding would likely impact saliva false-positive rates. In addition, because we could not know the excretion rate of CMV in the breast milk for the study cohort, we assumed a 100% excretion rate of CMV in colostrum.. However, because studies have demonstrated that between 10% and 50% of colostrum samples contain CMV DNA [7] [8] [9] , our calculations likely overestimated the contribution of CMV in colostrum to saliva false-positive test results. The need to confirm a positive saliva screening test within 3 weeks is a challenge that should be considered with a saliva-based newborn CMV screening approach.
Saliva CMV PCR for newborn screening is highly sensitive, and our data demonstrate it has acceptably low false-positive rates, even after adjusting for maternal CMV seroprevalence and expected breastfeeding rates. The low false-positive rates in our study suggests that saliva PCR results are unlikely to be significantly influenced by breastfeeding or other perinatal exposures. Even though the false-positive rates of saliva PCR testing are low, as with any screening test, it is prudent to confirm cCMV in all infants who screen positive for CMV. 
